XML 29 R16.htm IDEA: XBRL DOCUMENT v3.19.2
Goodwill, In-Process Research and Development and Intellectual Property
6 Months Ended
Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill, In-Process Research and Development and Intellectual Property
Goodwill, In-Process Research and Development and Intellectual Property
Goodwill
Goodwill of $93.8 million was recorded in connection with the Merger, as described in Note 1, goodwill of $38.3 million was recorded in connection with the Senhance Acquisition, as described in Note 3, and goodwill of $9.6 million was recorded in connection with the MST Acquisition, as described in Note 3. The carrying value of goodwill and the change in the balance for the six months ended June 30, 2019 is as follows:
 
Goodwill
 
(In thousands)
(unaudited)
Balance at December 31, 2018
$80,131
Foreign currency translation impact
(227
)
Balance at June 30, 2019
$79,904

Accumulated impairment of goodwill as of June 30, 2019 and December 31, 2018 was $61.8 million.
No impairment was recorded during the six months ended June 30, 2019 or 2018.
In-Process Research and Development
As described in Note 3, on October 31, 2018, the Company acquired the MST assets, technology and business from MST and recorded $10.6 million of IPR&D. The estimated fair value of the IPR&D was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flows were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development. The Company used a discount rate of 15% and cash flows that have been probability adjusted to reflect the risks of product integration, which the Company believes are appropriate and representative of market participant assumptions.
The carrying value of the Company’s IPR&D assets and the change in the balance for the six months ended June 30, 2019 is as follows:
 
In-Process
Research and
Development
 
(In thousands)
(unaudited)
Balance at December 31, 2018
$
10,747

Foreign currency translation impact
(80
)
Balance at June 30, 2019
$
10,667


Intellectual Property
As described in Note 3, on September 21, 2015, the Company acquired all of the developed technology related to the Senhance System and recorded $48.5 million of intellectual property. The estimated fair value of the intellectual property was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flows were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development. The Company used a discount rate of 45% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.
As described in Note 3, on September 21, 2015, the Company acquired all of the assets related to the Senhance System and recorded $17.1 million of IPR&D. The estimated fair value of the IPR&D was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flows were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development. The Company used a discount rate of 45% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions. On October 13, 2017, upon regulatory approval and the ability to commercialize the products associated with the IPR&D assets, the assets were deemed definite-lived, reclassified to intellectual property and are now being amortized based on their estimated useful lives.
The components of gross intellectual property, accumulated amortization, and net intellectual property as of June 30, 2019 and December 31, 2018 are as follows:
 
June 30, 2019
 
 
December 31, 2018
 
(In thousands)
(unaudited)
 
 
(In thousands)
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Foreign
currency
translation
impact
 
Net
Carrying
Amount
 
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Foreign
currency
translation
impact
 
Net
Carrying
Amount
Developed technology
$
66,413

 
$
(35,725
)
 
$
3,168

 
$
33,856

 
 
$
66,413

 
$
(30,550
)
 
$
3,495

 
$
39,358

Technology and patents purchased
400

 
(93
)
 
27

 
334

 
 
400

 
(72
)
 
30

 
358

Total intellectual property
$
66,813

 
$
(35,818
)
 
$
3,195

 
$
34,190

 
 
$
66,813

 
$
(30,622
)
 
$
3,525

 
$
39,716


The weighted average remaining useful life of the developed technology and technology and patents purchased was 3.3 years and 7.8 years, respectively as of June 30, 2019.  The weighted average remaining useful life of the developed technology and technology and patents purchased was 3.8 years and 8.3 years, respectively as of December 31, 2018.